CD274 and Miyoshi myopathy: As will be discussed later, clinically active agents blocking PD-1/PDL-1 axis have been associated with adverse events and are not approved for MM treatment; and ongoing studies are exploring the role of other potential immune checkpoint or agonist molecules including LAG 3 or TIGIT and OX40, respectively (24).